Anzeige
Mehr »
Login
Montag, 20.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
571 Leser
Artikel bewerten:
(2)

Capital Com SV Investments Limited: Capital.com And Newsquawk Forge Strategic Partnership To Empower Retail Traders With Real-Time News Feeds

Finanznachrichten News

Integration of Newsquawk's AI-powered news feeds will be made available to retail traders for the first time

LONDON, UNITED KINGDOM / ACCESSWIRE / August 8, 2024 / Capital.com, the global trading platform whose trading client volumes surpassed $1trn in 2023, today announced a strategic partnership with leading market real-time news platform, Newsquawk. With this partnership, Capital.com clients will have access to instant, market-moving news typically reserved for institutional and professional traders.

Through an API integration, Newsquawk feeds will be delivered directly via the Capital.com app and web platforms, enabling more than 500,000 retail clients to receive up-to-the-minute news feeds. This partnership marks an industry-first in the retail brokerage space, affirming Capital.com's commitment to help clients make informed trading decisions.

Dana Massey, Chief Product Officer, Capital.com, said:

"This partnership with Newsquawk reflects our ongoing commitment to support our traders with market-moving news and analysis to help inform their next move. This is the first time Newsquawk's institutional-grade service is being offered to retail traders and we are proud to be their partner in this journey. This is a massive step towards levelling the playing field, empowering traders to act with confidence and without delay."

Mehul Patel, Founder, Newsquawk, said:

"We are thrilled to work with Capital.com and extend our real-time news services to a broader audience. Powered by our proprietary news filtering technology and analysts, Newsquawk aggregates thousands of headlines and data releases across newswires, social media and live tv broadcasts to find the news that will move the market. Testament to the strength of our groundbreaking technology, Newsquawk has recently been awarded the prestigious 2024 UK Innovate Grant. We are excited to support Capital.com's retail clients and enhance their trading experience with rapid, reliable, and actionable news."

Niamh Byrne, Head of UK & Ireland, Capital.com, said:

"We have a long-standing partnership with Newsquawk in the UK, and our clients have always valued the service they provide. Recognising its importance, we decided to integrate Newsquawk into our web & mobile apps, ensuring all our clients can access the same reliable breaking news and alerts that institutional and professional traders depend on daily."

Key features of the partnership include:

Immediate Access to Market-Moving News: Capital.com traders will receive up-to-the-minute information that can impact market movements, incorporating both scheduled announcements and unscheduled news that could affect the markets.

Global Coverage: Traders will receive sector specific market coverage, including equities, currencies, commodities, and bonds, appealing to traders with diverse interests.

Expert Analysis: Access to expert commentary, produced by a team of qualified analysts, to help traders understand the implications of news events to support more informed trading decisions.

Headlines and Reports: Breaking news headlines and reports delivered directly to clients' mobile devices in multiple languages, helping them to trade the news without delay.

The integration will be rolled out in phases. The first phase, which includes access to Newsquawk's breaking news feeds, is currently available to all Capital.com clients actively trading on the platform. Further features of the product integration will be progressively rolled out over the coming months.

ENDS/

Media Contact

PR for Capital.com
Shamillia.sivathambu@capital.com
+44 7900 016 469

Notes to Editors

About Newsquawk

Newsquawk is a breaking financial news provider for institutional and professional traders. The company was recently awarded the prestigious 2024 Innovate UK Grant to develop its groundbreaking Large Language Model (LLM) project leveraging its proprietary data sets and market knowledge. LLMs, a subset of Artificial Intelligence(AI), are very large deep learning models that are pre-trained on vast amounts of data. Newsquawk's LLM(s) will leverage a decade of proprietary news data to provide traders with unparalleled and instantaneous context around market impacting events.

About Capital.com

Capital.com is a high-growth fintech company empowering people to participate in financial markets through simple and innovative online trading platforms. Launched in 2016, its intuitive award-winning platform -available on web and app -enables investors to trade thousands of world-renowned markets. To help investors trade with confidence, the platform is fitted with robust risk management controls, transparent pricing and extensive educational content to support clients in their trading journeys.

Capital.com has a global network with offices located in leading business and financial centres including London, Dubai, Warsaw, Vilnius, Sofia, Limassol, and Melbourne. Capital Com (UK) Limited is authorised and regulated by the Financial Conduct Authority (FCA) under registration number 793714. Capital Com SV Investments Limited is Authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC), under licence number 319/17. Capital Com Australia Pty Ltd is authorised and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL Number 513393. Capital Com Online Investments Ltd is a Company registered in the Commonwealth of The Bahamas and authorised to carry out Securities Business by the Securities Commission of The Bahamas with licence number SIA-F245. Capital Com Mena Securities Trading LLC is authorised and regulated by the Securities and Commodities Authority (SCA), under license number 20200000176.

To find out more, please visit: www.capital.com

This press release is for media use only. It's not intended for individual investors, and doesn't include personal advice or recommendations.

DISCLAIMER

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 83.51% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money. Professional clients can lose more than they deposit. All trading involves risk.

Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd. Spread bets are available only to UK clients.

The value of shares and ETFs bought through a share dealing account can fall as well as rise, which could mean getting back less than you originally put in. Past performance is no guarantee of future results.

Capital Com (UK) Limited ("CCUK") is registered in England and Wales with company registration number 10506220. CCUK is authorised and regulated by the Financial Conduct Authority ("FCA"), under registration number 793714. Capital Com SV Investments Limited ("CCSV") is registered in Cyprus with company registration number 354252. CCSV is regulated by Cyprus Securities and Exchange Commission (CySEC) under licence number 319/17. Capital Com Online Investments Ltd is a limited liability company (company number 209236B) registered in the Commonwealth of The Bahamas and authorised to carry on Securities Business by the Securities by the Securities Commission of The Bahamas ("SCB") with licence number SIA-F245. Capital Com Mena Securities Trading LLC is authorised and regulated by the Securities and Commodities Authority (SCA), under license number 20200000176.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as "investment research" has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.

SOURCE: Capital Com SV Investments Limited










View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.